52/ APRIL 2021 THE RIDER


Aservo™ EquiHaler™, industry-first therapy for severe equine asthma, now available in Canada


Aservo™ Equi-


Haler™, industry-first ther- apy for severe equine asthma, now available in Canada • Aservo™ EquiHaler™ (ci- clesonide inhalation solu- tion) leverages synergies between the company’s human pharma and animal health divisions to set new standards of care • An industry first in equine medicine, the inhaler ad- dresses an unmet need for horses with asthma. • The company continues to set new standards of care to strengthen its commitment to animal welfare. Burlington,


ON,


Canada, March 30, 2021 – Boehringer Ingelheim Ani- mal Health Canada Inc. has been granted marketing au- thorization for Aservo™ EquiHaler™, an inhaled therapy for horses with se- vere asthma. While inhaled thera-


pies for the treatment of asthma are common in human health, the Aservo™ EquiHaler™ marks an in- dustry first in equine medi- cine in Canada. Until now, there have been no approved inhalant therapies licensed for use in horses with equine asthma. Equine asthma leads


to inflammation of the air- ways which causes horses to experience


coughing,


wheezing, difficulty exercis- ing, slow recovery from ex- ercise and in severe cases


horses struggle to breathe, even at rest.1 It affects 11- 17 percent of horses.2,3 Developed after more


than a decade of collabora- tion between Boehringer In- gelheim’s


Pharmaceutical and Animal Health businesses,


Human the


Aservo™ EquiHaler™ inte- grates the Soft Mist™ tech- nology from the human Respimat® inhaler allowing medication to be inhaled deep into a horse’s lungs. It is designed specifically for horses, with a nostril adap- tor that fits gently in the nose of the horse for direct delivery of the medicated mist.


“Humans and animals


are connected in deep and complex ways, and we know that when animals are healthy, humans are health- ier too,” said Randy Trum- pler, Business Unit Director, Equine, Boehringer Ingel- heim Animal Health Canada. “The Aservo™ EquiHaler™ is a great ex- ample of how Boehringer Ingelheim is helping en- hance wellbeing through in- novative solutions that truly benefit horses and their owners.” Equine asthma is


often triggered by exposure to high concentrations of airborne dust particles, which leads to obstruction of the lower airways. These particles are commonly found in hay and bedding. The active ingredient


recurrent airway obstruction in North American horses: 1,444 cases (1990-1999). J Am Vet Med Assoc 2003;223:1645–50. 3 Wasko, A.J., Barkema, H.W., Nicol, J., Fernandez, N., Logie, N. and Léguil- lette, R., 2011. Evaluation of


in the Aservo™ Equi- Haler™ is ciclesonide, a corticosteroid that is only activated once it reaches the lung, where it reduces the lower airway inflammation associated with equine asthma. Aservo™ Equi-


Haler™ was developed with sustainability in mind. The Soft Mist™ technology de- livers medication in a fine mist generated by tension, not propellants, so it does not produce greenhouse gas emissions. The inhaler has been responsibly manufac- tured with the body of the inhaler made from up to 50% recycled materials. In


Boehringer


addition, Ingelheim


Canada has partnered with TerraCycle to introduce a national recycling program for used Aservo™ Equi- Haler™ devices. Veterinari-


ans and horse owners can send in their used Aservo™ EquiHaler™ to


be


processed and diverted from landfill sites. Once col- lected, the plastic material is melted down, formed into pellets and shaped into hard plastic to be used in items like shipping pallets and park benches. “Aservo™ Equi-


Haler™ is an innovative therapy made possible by years of research and collab- oration,” Trumpler said. “Not only will it offer the promise of relief to horses with severe asthma, our commitment to sustainabil- ity ensures it is produced re- sponsibly and can be kept out of landfill sites with our recycling program.” The


approval of


Aservo™ EquiHaler™ comes following a joint sub- mission from Boehringer In-


gelheim in Canada and the United States that saw regu- latory agencies from both countries participate in a collaborative


review


process. The regulatory agencies for each country maintained the right to de- termine whether a product was approved for its own market. The joint submis- sion and simultaneous re- view mark an important achievement in international regulatory cooperation.


References 1Couëtil, L.L., Cardwell, J.M., Gerber, V., Lavoie, J.P., Léguillette, R., Richard, E.A. (2016) ‘Inflammatory Airway Disease of Horses – Revised Consensus State- ment’, Journal of Veterinary Internal Medicine, 30, pp. 503-515. 2 Couëtil, L.L., Ward MP. Analysis of risk factors for


New ‘staycation’ Science Supplements


September tour to be held at Hickstead, with over £70,000 on offer


Hickstead’s popular


September national champi- onships will run over two weeks this season. The Science Supple-


ments All England Septem- ber Tour will take place from the 1-5 and the 8-12 September, giving riders the chance to stay and compete at Hickstead for two consec- utive weeks. Increased prize money will make it one of the UK’s most lucrative na- tional showjumping cham- pionships, with a total prize fund of more than £70,000 on offer. In spring and autumn,


many showjumpers travel to Europe to compete on ‘sun- shine tours’, where one venue will host competi- tions over a number of con- secutive weeks. But an increasing number of British venues are offering such tours, encouraging rid- ers to stay in the UK to com- pete and avoid the high costs of travelling abroad. “We felt there was a


real demand for a short tour in Britain, and it made sense to expand our hugely popu- lar September show to run across two weeks,” says Hickstead Director Lizzie Bunn.


The prize fund for the


vital to support the grass- roots of our sport and I am delighted to further extend our sponsorship for amateur riders,” said David Mitson, Group CEO of Science Sup- plements. Al Shira’aa continue


their sponsorship of the age championships across the season with classes for four- , five-, six- and seven-year- olds scheduled for both weeks. A nomination to one of the Al Shira’aa stallions – Tsunami de Hus, SS Pega- sus or Kratos FH – will be awarded to the highest placed mare in the Al Shira’aa Five, Six and Seven Year Old Champi- onships. “Our national show


The new Science Supplements All England September Tour at Hickstead will take place over two weeks this season (c) Julian Portch


Science Supplements All England September Tour has been given a significant boost, thanks to the title sponsors. The first week of the show will conclude with the Science Supplements Trophy, a 1.40m Grand Prix with a £6,000 prize fund; while the second week fin- ishes with the Science Sup- plements 1.40m Grand Prix.


This class will have a £9,000 prize fund with £3,000 to the winner, plus qualification for the first three prize winners for the Science Supplements Queen Elizabeth II Cup 2022. In addition, Science


Supplements have created the “Science Supplements Grand Slam” with a total bonus prize fund of £10,000


for combinations that can win their respective classes in both weeks of the Cham- pionship, including amateur classes. “Hickstead is without the most


doubt iconic


showjumping venue in the UK and we should be en- couraging our best horses and riders to compete on home soil. In addition, it is


has always attracted thou- sands of entries, and we hope this new two-week format will encourage even more riders to make the journey to West Sussex to compete here at Hickstead. We will be offering a dis- count for people who book stabling for both weeks, plus we plan to have various trail rides and arenas open for schooling during the two-day hiatus from compe- tition,” Lizzie adds. For more information


visit www.hickstead.co.uk.


a risk-screening question- naire to detect equine lung inflammation: results of a large field study. Equine veterinary journal, 43(2), pp.145-152. Aservo™, EquiHaler™ and Soft Mist™ are trademarks of Boehringer Ingelheim Vetmedica GmbH, used under license.


Boehringer Ingelheim An- imal Health The lives of animals


and humans are intercon- nected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 9,700 employees are dedicated to delivering value through innovation, thus enhancing the well- being of both. Respect for animals,


humans and the environ- ment is at the heart of what we do. We develop solutions and provide services to pro- tect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society- threatening diseases. Boehringer Ingelheim


Animal Health is the second largest animal health busi- ness in the world, with net sales of 4.1 billion euros in 2020 and presence in more than 150 countries. For more information i


v s i t :


http://www.boehringer-in- ge lhe im. com/ anima l - health/overview


Boehringer Ingelheim


(Canada) Ltd. Boehringer Ingelheim


is working on breakthrough therapies that improve the lives of humans and ani- mals. As a leading research- driven biopharmaceutical company, the company cre- ates value through innova- tion in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer In- gelheim takes a long-term perspective. Approximately 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health and Biopharmaceuti- cal Contract Manufacturing. The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingel- heim employs approxi- mately 600 people across Canada. Learn more at www.boehringer-ingel- heim.ca.


Ontario Racing continues to support


horsepeople throughout the Province


TORONTO, ON – April 15, 2021 – Ontario Racing is continuing to communicate with the Ontario Govern- ment in regards to vaccinations for horsepeople, the need for the safe return of live racing, and the industry’s on- going commitment to the highest standards of health and safety throughout the pandemic. Over the past 13 months, Ontario Racing, the


voice of the Ontario horse racing industry, has been in constant contact with various elected officials, providing updates and information on how the industry has been affected by COVID-19, and the measures it has taken to conduct all aspects of racing in the safest manner. Recently, Ontario Racing announced that Stan-


dardbred horsepeople have the opportunity to receive equine benefit payments (for cancelled April race dates) as a result of the suspension of live racing in the province due to the COVID-19 pandemic, through certain purse funds that remain available under the Funding Agree- ment with Ontario Lottery and Gaming Corporation (OLG). It is our expectation that equine benefit funds will continue to be distributed through the lockdown pe- riod.


Ontario Racing is also actively working with in-


dustry partners, and others, in an effort to determine the potential for equine-related support payments for Ontario Thoroughbred horsepeople. With Ajax Downs’ opening day of racing scheduled for May 12, preliminary discus- sions with Quarter Horse representatives will take place in the near future, should the current lockdown measures be extended. Ontario Racing will provide horsepeople with up-


dates regarding vaccinations, the resumption of live rac- ing, and any other important details, as they become available. “It has been an extremely difficult past 13-plus


months for the many hardworking horsepeople in our in- dustry whose livelihoods have been severely impacted by the pandemic,” said John Hayes, Chair, Ontario Rac- ing. “We remain dedicated to ensuring the best interests of horsepeople are both heard and understood.”


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54